The granting of the patent to Immatics Biotechnologies for its peptides and cell-based medicaments is a positive development for the company. This patent could potentially strengthen its position in the immunotherapy market, as it provides protection for its intellectual property and may lead to increased interest from investors. As a result, the stock price of IMTX is likely to go up in the short term.